In one of the biggest breakthroughs in schizophrenia research in recent times, Professor Cynthia Shannon Weickert at Neuroscience Research Australia (NeuRA) has identified immune cells in greater amounts in the brains of some people with schizophrenia. The study published today in Molecular Psychiatry has the potential to transform global schizophrenia research and open new avenues for developing targeted immune cell therapies.
One in every 100 Australians lives with schizophrenia. No single cause of schizophrenia has been identified, and this has prevented the development of a cure. The current treatments for schizophrenia are designed to suppress symptoms rather than target underlying causes of the disorder. These drugs only partially relieve symptoms and can produce unwanted side effects.
To recognise the significance of this discovery Professor Shannon Weickert says you first need to understand most scientists have had a long held belief that immune cells were independent from the brain pathology in psychotic illnesses.
“In our study, we challenged this assumption that immune cells were independent of the brain in psychiatric illness and made an exciting discovery. We identified immune cells as a new player in the brain pathology of schizophrenia,” said Professor Shannon Weickert.
Current schizophrenia research has focused on the status of three brain cells: the neurons; the glial cells, which support the neurons; and the endothelial cells, which coat the blood vessels. Employing new molecular techniques allowed Professor Shannon Weickert and her team to identify the presence of a fourth cell, the macrophage, a type of immune cell in the brain tissue of people with schizophrenia who show high levels of inflammation.
Professor Shannon Weickert said immune cells have previously been ignored as they had long been viewed simply as travelers just thought to be passing by, undertaking surveillance work. They have never been a suspect until now.
“To find immune cells along the blood brain barrier in increased amounts in people with schizophrenia is an exciting discovery. It suggests immune cells themselves may be producing these inflammatory signals in the brains of people living with schizophrenia,” said Professor Shannon Weickert.
“We have observed in people with schizophrenia, the glial cells, one of the local residents, become inflamed and produce distress signals which change the status of the endothelial cells.
“We think this may cause the endothelial cells to extend sticky tentacles, so when the immune cells travel by some are captured. These cells may transmigrate across the blood brain barrier entering the brain in greater amounts in some people with schizophrenia compared to people without the disorder.”
This discovery shows that specific immune cells are in the brains of some people with schizophrenia in close enough proximity to the neurons to do damage.
Professor Peter Schofield, CEO of NeuRA said this innovative new research has the ability to alter the way in which we may be able to diagnose and treat schizophrenia.
“This breakthrough demonstrates the value of the NSW Government’s support for Professor Shannon Weickert as NSW Chair of Schizophrenia Research, which has delivered new insights that the community seeks,” said Professor Schofield.
Professor Shannon Weickert is encouraging a cross-collaborative approach between neuroscientists and immunologists globally, to work together to develop treatments targeting this abnormal immune pathology of schizophrenia.
“This opens whole new avenues for therapy, because it suggests that the pathology of schizophrenia could be within the immune cells and the immune cells could be contributing to the symptoms of schizophrenia,” said Professor Shannon Weickert.
Professor Shannon Weickert is uniquely motivated in her work, with her twin-brother being diagnosed with schizophrenia when he was 17 years old.
Learn more: Schizophrenia breakthrough
The Latest on: Schizophrenia
via Google News
The Latest on: Schizophrenia
- Alkermes submits NDA for ALKS 3831 for schizophrenia and bipolar I disorderon November 19, 2019 at 4:54 am
Alkermes (NASDAQ:ALKS) has submitted a New Drug Application (NDA) to the FDA seeking approval of ALKS 3831 (olanzapine/samidorphan) for the treatment of schizophrenia and for the treatment of bipolar ...
- Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia andon November 19, 2019 at 4:06 am
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder PR Newswire DUBLIN, Nov. 19, 2019 DUBLIN, Nov. 19, 2019 ...
- Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorderon November 19, 2019 at 4:05 am
DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ...
- New Schizophrenia Study May Usher in Game-Changing Standard of Careon November 18, 2019 at 6:22 pm
In the case of Karuna Therapeutics, Inc. (NASDAQ: KRTX), a fairly recent initial public offering, news that KarXT demonstrated statistically significant and clinically meaningful improvement in a ...
- Karuna Therapeutics News: KRTX Stock Skyrockets 415% on Positive Schizophrenia Trialon November 18, 2019 at 12:24 pm
The big Karuna Therapeutics news is that the study for using KarXT to treat acute psychosis in patients with schizophrenia was a success. This saw it met the primary endpoint of the study. The study ...
- Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophreniaon November 18, 2019 at 9:04 am
This combination has the potential to be a new option for treating the difficult symptoms of debilitating CNS disorders, such as schizophrenia, without subjecting patients to the problematic side ...
- Comparative genetic architectures of schizophrenia in East Asian and European populationson November 18, 2019 at 8:09 am
Schizophrenia is a debilitating psychiatric disorder with approximately 1% lifetime risk globally. Large-scale schizophrenia genetic studies have reported primarily on European ancestry samples, ...
- Karuna Therapeutics Shares Rip Higher After Schizophrenia Drug Aces Midstage Trialon November 18, 2019 at 6:39 am
Boston, Massachusetts-based Karuna said the Phase 2 clinical trial that evaluated its lead candidate KarXT for the treatment of acute psychosis in patients with schizophrenia met the primary endpoint.
- A new approach to treating schizophrenia delivers positive results in mid-stage trialon November 18, 2019 at 3:07 am
Boston-based biotech Karuna Therapeutics (KRTX) said Monday that a novel combination pill achieved the main goal of a mid-stage clinical trial by reducing the acute psychosis and related symptoms ...
via Bing News